- Home
- KEN vs XNCR Comparison
KEN vs XNCR Comparison
Compare KEN & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KEN
- XNCR
- Stock Information
- Founded
- KEN 2014
- XNCR 1997
- Country
- KEN Singapore
- XNCR United States
- Employees
- KEN N/A
- XNCR N/A
- Industry
- KEN Electric Utilities: Central
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- KEN Utilities
- XNCR Health Care
- Exchange
- KEN Nasdaq
- XNCR Nasdaq
- Market Cap
- KEN 1.5B
- XNCR 1.7B
- IPO Year
- KEN N/A
- XNCR 2013
- Fundamental
- Price
- KEN $32.01
- XNCR $24.80
- Analyst Decision
- KEN
- XNCR Strong Buy
- Analyst Count
- KEN 0
- XNCR 9
- Target Price
- KEN N/A
- XNCR $36.33
- AVG Volume (30 Days)
- KEN 10.0K
- XNCR 775.3K
- Earning Date
- KEN 01-03-2025
- XNCR 11-06-2024
- Dividend Yield
- KEN 11.87%
- XNCR N/A
- EPS Growth
- KEN N/A
- XNCR N/A
- EPS
- KEN 3.23
- XNCR N/A
- Revenue
- KEN $742,796,000.00
- XNCR $85,164,000.00
- Revenue This Year
- KEN N/A
- XNCR N/A
- Revenue Next Year
- KEN N/A
- XNCR $89.22
- P/E Ratio
- KEN $9.81
- XNCR N/A
- Revenue Growth
- KEN 8.29
- XNCR N/A
- 52 Week Low
- KEN $19.63
- XNCR $15.31
- 52 Week High
- KEN $32.17
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- KEN 68.86
- XNCR 53.58
- Support Level
- KEN $28.74
- XNCR $22.74
- Resistance Level
- KEN $30.20
- XNCR $24.94
- Average True Range (ATR)
- KEN 0.77
- XNCR 1.20
- MACD
- KEN 0.00
- XNCR -0.18
- Stochastic Oscillator
- KEN 95.34
- XNCR 53.51
About KEN Kenon Holdings Ltd.
Kenon Holdings Ltd is a holding company that operates dynamic, growth-oriented, businesses. The company's operating segments include OPC; CPV Group; and ZIM. It generates maximum revenue from the OPC segment. OPC operates in the Israeli electricity generation sector, including initiating, developing, constructing, and operating power plants and selling and supplying electricity. Geographically, it derives a majority of its revenue from Israel.
About XNCR Xencor Inc.
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases such with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045, XmAb662 among others. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.